Alpha Cognition Presenting at the Benzinga Biotech Small Cap Conference

March 22, 2021 9:03 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Detroit, Michigan--(Newsfile Corp. - March 22, 2021) - Alpha Cognition Inc. ("ACI"), a biopharmaceutical company with near term commercialization potential for its lead drug candidate ALPHA-1062, announced today that Dr. Fred Sancilio, ACI's President will be presenting at the Benzinga Biotech Small Cap Conference on March 24th, 2021 at 10:55 AM EST. The presentation will cover key areas of ACI's business and the ALPHA-1062 development plan for the treatment of Alzheimer's dementia.

We invite our shareholders, and all interested parties to register for our presentation at the spectator link for the event:

About Alpha Cognition Inc.

Alpha Cognition is a clinical stage, biopharmaceutical company dedicated to developing treatments for under-served neurodegenerative diseases such as Alzheimer's Disease and Amyotrophic Lateral Sclerosis.

ALPHA-1062, a patented new chemical entity that has demonstrated safety and improved tolerability in human clinical trials. It is being developed as a new acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer's type, with minimal gastrointestinal side effects and novel routes of administration.

ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein, and is in preclinical development for the treatment of ALS. ALPHA-0602 is patented and has received Orphan Drug Designation from the FDA.

For further information:

Bristol Investor Relations
Stefan Eftychiou
905 326 1888 ext 6

To view the source version of this press release, please visit

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Newsfile, Press Releases

Related Entities